Vistagen Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Vistagen Therapeutics

13/08/2024 22:57

* Vistagen Therapeutics Inc  VTGN.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
June.  The mean expectation of two analysts for the quarter was
for a loss of 40 cents per share. Wall Street expected
results to range from -41 cents to -40 cents per share.
    * Revenue was $84.00 thousand​; analysts expected $300.00
thousand. 
    * Vistagen Therapeutics Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The company reported a quarterly loss of $10.73 million.
    * Vistagen Therapeutics Inc shares had fallen by 3.2% this
quarter and lost 34.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 9.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Vistagen
Therapeutics Inc is $12.00 
This summary was machine generated from LSEG data August 13 at
09:56 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.40          -0.35          Beat
 Mar. 31 2024      -0.36          -0.25          Beat
 Dec. 31 2023      -0.30          -0.22          Beat
 Sep. 30 2023      -0.68          -0.66          Beat